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Introduction: Mild therapeutic hypothermia (MTH) is being used after cardiac arrest for its expected improvement
in neurological outcome. Safety of MTH concerning inducibility of malignant arrhythmias has not been satisfactorily
demonstrated. This study compares inducibility of ventricular fibrillation (VF) before and after induction of MTH in a
whole body swine model and evaluates possible interaction with changing potassium plasma levels.
Methods: The extracorporeal cooling was introduced in fully anesthetized swine (n = 6) to provide MTH. Inducibility
of VF was studied by programmed ventricular stimulation three times in each animal under the following: during
normothermia (NT), after reaching the core temperature of 32°C (HT) and after another 60 minutes of stable
hypothermia (HT60). Inducibility of VF, effective refractory period of the ventricles (ERP), QTc interval and
potassium plasma levels were measured.
Results: Starting at normothermia of 38.7 (IQR 38.2; 39.8)°C, HT was achieved within 54 (39; 59) minutes and
the core temperature was further maintained constant. Overall, the inducibility of VF was 100% (18/18 attempts) at
NT, 83% (15/18) after reaching HT (P = 0.23) and 39% (7/18) at HT60 (P = 0.0001) using the same protocol. Similarly,
ERP prolonged from 140 (130; 150) ms at NT to 206 (190; 220) ms when reaching HT (P < 0.001) and remained
206 (193; 220) ms at HT60. QTc interval was inversely proportional to the core temperature and extended from
376 (362; 395) at NT to 570 (545; 599) ms at HT. Potassium plasma level changed spontaneously: decreased
during cooling from 4.1 (3.9; 4.8) to 3.7 (3.4; 4.1) mmol/L at HT (P < 0.01), then began to increase and returned to
baseline level at HT60 (4.6 (4.4; 5.0) mmol/L, P = NS).
Conclusions: According to our swine model, MTH does not increase the risk of VF induction by ventricular pacing in
healthy hearts. Moreover, when combined with normokalemia, MTH exerts an antiarrhythmic effect despite prolonged
QTc interval.
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Mild therapeutic hypothermia (MTH) is recommended in
patients remaining comatose after cardiac arrest caused by
ventricular fibrillation (VF) [1-5] and should be consid-
ered in those with other presenting rhythms [6-8]. Ac-
cording to animal studies [9-13], early induction of MTH
is supposed to be beneficial, but clinical trials did not
prove it consistently yet [14-17]. Consequently, earliest
possible induction of MTH is emphasized in some recent
protocols using nasopharyngeal evaporative cooling and
peripheral veno-arterial extracorporeal membrane oxy-
genation (ECMO) hoping to improve the neurological
outcome [18-22]. On the other hand, the occurrence of
malignant ventricular tachyarrhythmias during MTH still
remains a major cause of death considering predisposing
factors such as myocardial ischemia/reperfusion damage,
often reported hypokalemia during the cooling phase
[23-25], slowing of the heart rate and QT interval pro-
longation [25-29].
The aim of this experimental study was to assess the safety
of MTH in terms of inducibility of malignant ventricular
tachyarrhythmias in relation to spontaneous changes of
potassium plasma level and QT interval in a whole body
pig model. We hypothesized that MTH related hypokal-
emia together with prolongation of the QT interval might
predispose the heart to greater electrical instability and
lower VF threshold.
Methods
The experimental protocol was designed to perform
electrophysiological (EP) study before and after the in-
duction of MTH using ECMO to provide cooling and
hemodynamic support during the stimulation protocol
and arrhythmias. All experiments were performed on
cross-bred swine (Landrace x White) in an accredited
university experimental laboratory by the skilled team of
intensive care specialists and laboratory and veterinary
technicians. The animals were handled in accordance
with the guidelines of research animal use [30]. The
protocol was approved by the Charles University First
Faculty of Medicine Institutional Animal Care and Use
Committee and performed at the Animal Laboratory,
Department of Physiology, First Faculty of Medicine,
Charles University in Prague in accordance with Act No
246/1992 as amended, Collection of Laws, Czech Republic,
that is harmonized with EU Directives 86/609/EEC as
amended, 2007/526/ES, 2010/63/EU.
Anesthesia and monitoring
After intramuscular sedation and premedication (azaper-
one 2–3 mg/kg, ketamine 20 mg/kg all i.m.) the marginal
ear vein was cannulated and the pigs were preoxygenated
with 100% oxygen via a facial mask. General anesthesia
was induced by intravenous bolus of propofol (1–2 mg/kg)and orotracheal intubation was performed. Mechanical
ventilation was adjusted by Intellivent-ASV closed-loop
system (G5, Hamilton Medical, Bondauz, Switzerland)
to maintain normoxia (SpO2 > 97%, pO2 100 mmHg)
and normocapnia (EtCO2 38–40 mmHg) respecting the
actual metabolic rate. The total intravenous anesthesia
was maintained by continuous administration of propofol
(6–12 mg/kg/h) and morphine (0.1-0.2 mg/kg/h), pipe-
curonium boluse (4 mg i.v.) were applied when shivering
occurred during MTH. The depth of anesthesia was regu-
larly assessed by the photoreaction and the corneal reflex
and adjusted accordingly. Intravenous infusion of Ringer’s
solution was given to reach and maintain central venous
pressure between 6 and 8 mmHg. Anticoagulation was
provided by unfractionated heparin bolus (100 IU/kg i.v.)
followed by continuous intravenous drip (40–50 IU/kg/h)
to maintain target activated clotting time 180–250 seconds
(values checked every hour with Hemochron Junior+,
International Technidyne Corporation, USA). Sheaths and
catheters were inserted to femoral and carotid/jugular ves-
sels as needed. Invasive blood pressure from carotid and
pulmonary artery, central venous pressure (TruWave,
Edwards Lifesciences, USA), body surface ECG, capno-
metry and pulse oximetry were continuously monitored
by bedside monitor (Life Scope TR, Nihon Kohden,
Japan) and trends were recorded. Mixed venous oxim-
etry (SvO2), continuous cardiac output and pulmonary ar-
tery temperature were recorded using Swan-Ganz Combo
V cathether (Vigilance monitor, Edwards Lifesciences,
USA). A diagnostic decapolar catheter (Response CSL, St.
Jude Medical, USA) was inserted under fluoroscopic guid-
ance into the apex of the right ventricle (RV) via jugular
vein to provide monitoring of intracardial electrograms
and to induce VF. Five bipolar channels were recorded
from the apex to base of RV at 3 kHz sampling rate. Heart
rate and QT interval were manually measured and QTc
was calculated using Bazett’s formula (QT interval divided
by square root of RR interval). Before starting the proto-
col, cardiopulmonary bypass was established (Figure 1): an
inlet 19 F cannula was inserted via femoral vein into the
right atrium and an outlet 17 F cannula into abdominal
aorta via femoral artery. The cannulae were connected to
ECMO circuit consisting of a blood pump (Levitronix
Centrimag, Levitronix, USA) and oxygenator (Quadrox,
Maquet, Germany). A custom made cooling system was
connected to the oxygenator. The cooling system con-
sisted of a rotary pump and reservoir (volume of 15 L)
filled with refrigerated water with ice cubes, which were
gradually supplemented to keep the temperature of the
coolant between 4 and 6°C. The coolant flow rate was set
up to approximately 2 L/min during the cooling phase a
consequently was slowed as needed to maintain the core
temperature of 32°C. The ECMO circuit was primed with
500 mL of normal saline with 2500 IU of unfractionated
Cooling liquid
(water + ice)







Q ~ 2 L/min 
Air + O2
Figure 1 V-A ECMO circuit. Blood is pumped from the right atrium
via oxygenator where blood is cooled and gases are exchanged
into abdominal aorta. The custom made cooling circuit was
assembled from the pump and reservoir filled with refrigerated
water and melting ice. RA indicates right atrium; Ox, oxygenator;
Ao, abdominal aorta.
Kudlicka et al. Journal of Translational Medicine  (2015) 13:72 Page 3 of 8heparin. The ECMO blood flow was empirically set at
40 mL/kg/min to provide the cooling and to prevent low
cardiac output and hypotension during the stimulation
protocol. After the onset of VF, the flow was increased to
80–100 mL/kg/min as needed to keep mean arterial pres-
sure of 60 mmHg until an effective pulsatile sinus rhythm
with mean arterial pressure above 60 mmHg was restored.
Blood gasses, pH and potassium plasma levels were con-
tinuously sampled and recorded in ECMO circuit by a
real-time analyzer (CDI 500, Terumo, Japan). At baseline
and during the experiment was the real-time analyzer cali-
brated in 15 minute intervals using a bedside blood ana-
lysis system (IRMA TruPoint, International Technidyne
Corporation, USA). Despite the expected hypokalemia
during MTH, no potassium was replaced during thewhole protocol, therefore all changes of potassium plasma
levels were spontaneous. Ventilation support, as well as
ECMO gas flow, was regularly adjusted to reach the target
values (pH 7.4, pO2 100 mmHg and pCO2 38-40 mmHg).
Electrophysiological study
VF was induced by programmed ventricular stimulation
(PVS, Figure 2B). Briefly, electrical stimuli (12 ms dur-
ation, maximal stimulation current 20 mA) were delivered
from the apex of RV. Eight basic stimuli (S1) of cycle
length 350 or 400 ms according to the heart rate were
coupled with up to 4 extrastimuli (S2-S5). The coupling
interval of S2 was decreased at 10 ms steps until the ven-
tricular effective refractory period (ERP) was achieved. S2
coupling interval was then set to 10 ms above ERP and
analogically S3 or S4 stimuli were delivered until VF or
absolute ventricular refractory period (ARP) was reached.
There were at least 10 s intervals between pacing se-
quences. VF was defined as an orderless rhythm without
detectable QRS complexes lasting longer than 30 s. Nor-
mal SR was restituted by the transcutaneous defibrillation
using pads placed in the conventional position sternum -
apex (TEC-5521, Nihon Kohden, Japan). Biphasic shocks
with rising energy (100-150-200-270 J) were delivered as
needed. Another PVS procedure was performed at least
10 minutes after SR restoration in a previous one.
Protocol
EP study began at minimum of 60 minutes after con-
necting ECMO. After the completion of 3 PVS proce-
dures at the baseline (normothermia, NT), the cooling
was started and other 3 PVS procedures were performed
after reaching the core temperature of 32°C in pulmon-
ary artery (hypothermia, HT). Finally, 3 PVS procedures
were carried out after 60 minutes of stable hypothermia
(HT60), Figure 2A.
Statistics
Data are presented as median (interquartile range). Each
animal was used as its own control and nonparametric
pair Friedman test with Dunn’s multiple comparison post
test were performed to assess the differences. The linear
regression of the dependence of QTc interval on body
temperature was performed after passing D’Agostino &
Pearson omnibus normality test. The comparison of the
VF inducibility was performed by Fisher’s exact test. The
P values < 0.05 were considered significant. Statistical ana-
lysis and graphs were performed using Prism 5.0 (GraphPad,
La Jolla, CA, USA).
Results
Overall, we used 7 animals (female, 4–5 months old, mean
weight 51 ± 2 kg). One of them was excluded from ana-





















Figure 2 Diagram of study protocol (A) and electrophysiological study (B). GA indicates induction of general anesthesia; ECMO, initiation of
ECMO; EP study, electrophysiological study; HT, hypothermia (core temperature of 32°C); 8 × S1, train of eight basic stimuli; S2-5, up to five
extrastimuli; ERP, effective refractory period; ARP, absolute refractory period; VF, ventricular fibrillation; defib, defibrillation; steady, steady
state; ECMO high, increasing of the ECMO flow to 80-100 mL/kg/min after onset of VF until the sinus rhythm was restored.
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ing, the core body temperature dropped from normother-
mia of 38.7 (38.2; 39.8)°C to 32°C during 54 (39; 59)
minutes and was further maintained constant at 31.9 (31.8;
32.0)°C, Figure 3. The potassium plasma level decreased
along with the body temperature decline from basal 4.1
(3.9; 4.8) mmol/L to 3.7 (3.4; 4.1) mmol/L (P < 0.01) when
reaching HT. In 3 of 6 animals (50%) dropped plasmatic
potassium below 3.5 mmol/L, but none of them reached
severe hypokalemia (<3.0 mmol/L). Subsequently, during
maintaining of HT the potassium plasma level increased
spontaneously again and at HT60 was similar to baseline
level (4.6 (4.4; 5.0) mmol/L, P =NS, Figure 4A). Heart rate
decreased from 148 (123; 161) at baseline to 85 (82; 100)
beats per minute at HT (P < 0.001) and remained similar

































Figure 3 The time dependence of the plasma potassium level
and body temperature after the start of the cooling (time = 0).
Data are expressed as medians with interquartile ranges.was significantly inversely related to the body temperature
(−29 ± 2 ms per degree of Celsius, r2 = 0.82, Figure 5) and
increased from basal 376 (362; 395) ms to 570 (545; 599)
ms at HT. ERP adjusted to S1-S1 cycle length of 350 ms
increased from 140 (130; 150) ms at NT to 206 (190; 220)
ms when reaching HT (P < 0.001) and remained constant
at HT60 (206 (193; 220) ms, Figure 4B). Through all the
experiments, no spontaneously originating or provoked
torsades de pointes (TdP) or heart conduction system dis-
orders were observed. The inducibility of VF at normo-
thermia was 100% (18/18 PVS), 83% (15/18 PVS) when
reaching HT, P =NS, and 39% (7/18 PVS) at HT60, P <
0.0001, Table 1, Figure 4C.
Discussion
In our experimental study we have proven that MTH is
safe in terms of inducibility of malignant ventricular
tachyarrhythmias in healthy pig hearts. Despite our hy-
pothesis, the inducibility of VF was not increased both
during the spontaneous transient decline of plasmatic po-
tassium level and concurrent significant prolongation of
QTc interval. Moreover, inducibility of VF was even sig-
nificantly lower after normalization of potassium plasma
level. Our data show that the potassium plasma level de-
clines during the cooling phase, while during maintenance
of MTH potassium plasma level rises spontaneously and
ultimately returns to the baseline value.
Regarding dependence of potassium plasma level on
body temperature, our data are concordant to clinical tri-
als by Miryozev et al. [25], Soeholm and Kirkegaard [24].
Nevertheless, none of the animals in our experiment
reached severe spontaneous hypokalemia (<3.0 mmol/L)




















































Figure 4 Changes in potassium plasma level (A), effective refractory period (B) and inducibility of ventricular fibrillation (C). Data are
expressed as medians with interquartile ranges. NT indicates normothermia; HT, after reaching the core temperature of 32°C; HT60, after
60 minutes of stable hypothermia; NS, statistically non-significant; *P < 0.01; **P < 0.001; ***P < 0.0001.
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mechanism of potassium plasma level changes remains
not fully elucidated. In our study we can exclude the
possible effects of drugs such as insulin, cathecholamines
or diuretics, as well as significant ischemic damage of
tissues or acid–base changes. Except for the suggested
temperature related potassium reversible intra and extra
cellular redistribution [31], Polderman et al. [32,33] docu-
mented hypothermia-induced polyuria caused by transient
tubular dysfunction during the cooling phase which dis-
appeared after maintaining MTH and rewarming. Based
on our data, despite hypokalemia as a potential physio-
logical phenomenon, maintaining the normokalemia
during MTH contributed to electric stabilization of the
myocardium. In accordance with other authors [25,27] we
assume that close monitoring of potassium plasma level
and its timely supplementation during the cooling phase
could help decrease the risk of malignant ventricular
arrhythmias.
As observed, the prolongation of QTc interval during
MTH had not an adverse effect on arrhythmogenesis of
ventricular arrhythmias. The QTc interval was inversely

















Figure 5 Dependence of QT on body temperature with linear
regression. Error bars show 95% of confidence interval.potassium plasma changes. Hypothermia related pro-
longation of QTc interval and decrease of heart rate
were previously described in beagle dogs [34] and also
in newborns [35]. According to our data the slope of the
curve corresponds to the results in newborns well (-29 ms
vs. -21 ms per degree of Celsius). Until recently, the occur-
rence of the long QT interval during MTH was consid-
ered to be a negative prognostic factor in terms of higher
incidence of TdP or VF [27,36]. However, recent observa-
tional studies and meta-analysis did not prove this as-
sumption [37-40]. Furthermore, as reported by Nishiyama
et al. in case reports of congenital long QT syndrome [41],
the induction of MTH after cardiac arrest did not have
a proarrhythmic effect. Despite prolongation of QTc inter-
val to extreme values during MTH, there were no recur-
rences of TdP documented. Similarly, in our experiments
we have not detected any spontaneous or induced TdP
taking into account the limitation in the use of healthy
pig hearts.
Decrease in heart rate during MTH might be affected
by decreased sympathetic activity as reported by Schwarzl
et al. [42], which could also contributed to decreased VF
inducibility. According to our previously published data,
significant prolongation of ERP was observed as a sign
of decreased sympathetic activity after renal denervation
[43]. Nevertheless, considering comparable heart rate and
ERP at HT and HT60 we can suppose that the tone of
autonomic nerve system remained unchanged and could
not play a major role in a significant decrease of VF induc-
ibility at HT60.
The influence of profound reduction of myocardial
temperature on VF was previously studied in more detail
by Chorro et al. [44] in rabbit hearts using high-resolution
epicardial mapping and transmural recordings of ven-
tricular activation. They described the antiarrhythmic ef-
fect of deep hypothermia (<20°C) by exponential decay of
VF dominant frequency, reduction in conduction velocity
and subsequently single wave front extinction on activa-
tion maps. More recently, Harada et al. [45] proved
Table 1 Characteristics of ventricular fibrillation induction
NT HT HT60
Animal # Induction parameter (ms) Inducibility
of VF
Induction parameter (ms) Inducibility
of VF
Induction parameter (ms) Inducibility
of VF
1 400/200/140/110/100 3/3 400/220/130 3/3 400/270/170/160 (ARP) 0/3
2 350/150/110 3/3 350/200/170/160 (ARP) 0/3 350/220/140/130 3/3
3 300/150/90/80 3/3 350/240/140/130 3/3 350/230/160/150 (ARP) 0/3
4 350/140/60 3/3 400/250/180/170 3/3 400/240/180/170/160 (ARP) 0/3
5 350/150/140 3/3 350/220/180 3/3 400/230/220 1/3
6 300/120/60 3/3 400/230/160/150 3/3 400/230/200/190 3/3
Total 100% (18/18) 83% (15/18) NS 39% (7/18)***
Induction parameters represent minimal cycle lengths of basic stimuli and extrastimuli. In each animal and condition was EP protocol made three times. NT
indicates normothermia; HT, after reaching the core temperature of 32°C; HT60, after 60 minutes of stable hypothermia. ARP indicates the achievement of
absolute refractory period; NS, statistically non-significant; ***P = 0.0001.
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both MTH and deep hypothermia caused significant pro-
longation of action potential duration and significant re-
duction of conduction velocity, the duration of induced
ventricular arrhythmias was significantly lower only in
MTH. As they observed by high-resolution optical poten-
tial mapping, MTH causes a modification of arrhythmia’s
spiral wave dynamics (annihilation or exit from the ana-
tomical boundaries) leading to the increase of the chance
of arrhythmia self-termination. This corresponds to the
results of our study on the pig whole body model.
This study has several translational aspects related to
post-resuscitation care. Frequent monitoring and ad-
equate substitution of plasmatic potassium seems to be
very important especially during the cooling phase to
prevent malignant ventricular arrhythmias. On the other
hand, close monitoring of QTc interval and premature
termination of MTH due to long QTc appears not to be
necessary. There is also potential in treating of incessant
ventricular arrhythmias resistant to treatment when
MTH could contribute to stabilization of the heart
rhythm.
Our study was limited by using healthy animals not
considering ischemic-reperfusion injury of the myocar-
dium during the acute myocardial infarction or other
predisposition for malignant ventricular arrhythmias.
Thus, the translation of the results to humans should be
interpreted with caution despite the fact, that our biomodel
was represented by a breed repeatedly validated for simula-
tion of human cardiac arrest and resuscitation [46,47]. The
number of experimental animals tested is low, however
multiple pairwise comparisons in individual animals coun-
terbalances this limitation. The speed of cooling compar-
ing ECMO cardiopulmonary resuscitation protocols [48]
was considerably lower. Unlike them, we used a half
ECMO flow (40 mL/kg/min) to prevent a hyperkinetic cir-
culation in respect to spontaneous hemodynamics and
also the priming the ECMO circuit with the precooledsaline could not be applied before. Further, no other ions
such as calcium or magnesium have been followed while
they might play a significant role. We also did not analyze
diuresis and ion excretion in urine. In present study, no
potential mapping technics were used to describe exact
mechanisms leading to antiarrhythmic effect of MTH pre-
ferring the complexity of the whole body biomodel than
open-chest or isolated heart techniques.
Conclusions
The induction of MTH in a swine model is safe with re-
spect to the inducibility of malignant ventricular arrhyth-
mias. Potassium plasma level decline during the cooling
phase does not impair VF threshold and after achieving
spontaneous normokalemia there is a significant effect
on the reduction of VF inducibility. Prolongation of QT
interval during MTH appears to be a physiological
phenomenon reflecting the conduction changes and does
not impair the inducibility of VF.
Key messages
 MTH does not increase the inducibility of VF in a
pig whole body model.
 Despite prolongation of QT interval, prolonged
MTH seems to have an antiarrhythmic effect.
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